Saturday , August 13 2022

Apurone® withdrawn from the market and restrictions on the use of fluoroquinolones – Antibiotics



[ad_1]

In a statement to health professionals, the National Agency for Pharmacological Safety (ANSM) informs them that the European Medicines Agency (EMA) has re-evaluated quinolones and has discovered that its benefit or risk is now unfavorable. But a new study on the risk / benefit ratio of antibiotics of quinolones and fluoroquinolones has led the health authorities to ban the first and reduce the use of this. The active substances affected in France are ciprofloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin and loxin. Although they are rare, their side effects can be serious, lasting, incapacitating and potentially irreversible. The cause is an incapacitating, lasting and potentially irreversible secondary effect.

Severe side effects include: tendonitis, tendon rupture, muscle aches, muscle weakness, arthralgia, swelling of the joints and walking disorders, peripheral neuropathy, insomnia, depression, fatigue, memory problems and vision problems, hearing, smell and taste Here is the withdrawal of the flumequina market. They are used to treat bacterial infections during which the vital prognosis can be hired. Therefore, it is not recommended to prescribe & # 39; ls for non-severe infections (pharyngitis, angina and acute bronchitis); prevent Diarrhea of ​​the traveler or recurrent infections of the lower urinary tract; to treat non-bacterial infections, for example, non-bacterial prostate (chronic); to treat mild to moderate infections (including uncomplicated cystitis, acute exacerbation of chronic bronchitis, and chronic obstructive pulmonary disease) [BPCO]rhinocino acute bacterial sinusitis and acute otitis media).


If you are currently dealing with any of these medications, you should consult your doctor as soon as symptoms such as pain or muscle weakness and pain or swelling in the joints appear.

[ad_2]
Source link